the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections. (UTOPIE)

University Hospital Center (CHU) Dijon Bourgogne

Status: Completed

Conditions: Community Infections

Treatments: Other: all children with at least one prescription of PPI; Other: all children with no prescription of PPI

Study type: Observational

Funder types: Other

Identifiers

NCT03134495

LUU 2017

Details and patient eligibility

About

Pharmacological treatment of physiologic Gastro-esophageal Reflux disease (GERD) is excessive in France, as 65%-85% of children below 11 years are being treated, frequently with Proton Pump Inhibitors (PPIs) PPI have been associated, in adults, with an increase of infection rate but data in pediatry are scarce, especially in community medecine. Recently a study conducted in England brought up controversial results suggesting that the use of PPIs can be associated with a reduced risk of community acquired pneumonia.

Our study was aimed to assess, on a population-based database, the association between PPI prescription and community infections in children of 11 years or under.

Enrollment: 290,286 patients

Sex: All

Ages: Under 11 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children aged 11 years or below with at least 2 consultations during the follow up

Exclusion criteria

• chronic pulmonary or cardiac
• muscoviscidosis
• immunodeficiency
• H. pylori infection
• Diabetes
• Denutrition
• known digestive upper tract malformation

Trial design

290,286 participants in 2 patient groups

PPI exposed children

Description:

all children with at least one prescription of PPI

Treatment:

Other: all children with at least one prescription of PPI

non-exposed children

Description:

all children with no prescription of PPI

Treatment:

Other: all children with no prescription of PPI